# Artelo Biosciences, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Artelo Biosciences, Inc). ## Overview Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system (ECS). Its pipeline is built around licensed and internally developed product candidates rather than marketed drugs, so the company is still in the research, preclinical, and clinical development phase. The company’s disclosed programs include ART12.11, a solid-state CBD composition co-formed with TMP being developed for anxiety disorders and rare/orphan diseases, and ART27.13, which is being advanced with third-party manufacturing support. Artelo’s strategy is to target validated biological pathways where it believes differentiated cannabinoid-derived or lipid-signaling therapies can address unmet medical needs. Because it has not yet generated product revenue, the business remains dependent on financing, licensing, and successful clinical execution. ## Products & services • ART12.11 solid-state CBD/TMP composition • ART27.13 clinical-stage product candidate • Lipid-signaling and ECS-based drug development • Licensing and development of pharmaceutical IP • Preclinical and clinical trial programs - **Clinical-stage product candidates** (0%) — Drug candidates under preclinical or clinical development, including ART12.11 and ART27.13. - **Licensed intellectual property** (0%) — In-licensed pharmaceutical and biotechnology IP used to build the pipeline. - **Research and development programs** (100%) — Discovery, preclinical studies, clinical trials, and regulatory preparation for future products. - ART12.11 solid-state CBD/TMP composition - ART27.13 clinical-stage product candidate - Lipid-signaling and ECS-based drug development - Licensing and development of pharmaceutical IP - Preclinical and clinical trial programs ## Customers Artelo does not currently sell commercial products, so its direct customers are not end-market patients today. In the future, if approved, its therapies would be prescribed by physicians and dispensed through regulated healthcare channels for conditions such as anxiety, pain, inflammation, neurological disease, epilepsy, dermatologic conditions, and rare/orphan diseases. The company also relies on licensors, contract manufacturers, clinical trial vendors, and research partners as critical counterparties in its development model. Commercial success would depend on physicians, payers, and healthcare systems accepting the clinical value and reimbursement profile of any approved product. For now, the company’s 'customers' are effectively the scientific, regulatory, and partnering stakeholders needed to advance its pipeline. - **Future prescription patients** (primary) — Patients who may receive approved Artelo therapies for anxiety, rare/orphan diseases, pain, inflammation, neurological disease, epilepsy, or dermatologic conditions. - **Physicians and specialists** (primary) — Prescribers who would adopt the company’s therapies if clinical data support efficacy, safety, and differentiation. - **Payers and reimbursement bodies** (secondary) — Insurers and health systems that would influence market access and uptake through coverage decisions. - **Clinical development partners** (primary) — CROs, trial sites, and investigators that execute studies and generate the data needed for approvals. - **Licensing and manufacturing partners** (primary) — Third parties that provide IP, manufacturing, and commercialization support to advance product candidates. - Physicians who would prescribe approved therapies for specific indications - Patients with anxiety, pain, inflammation, epilepsy, or rare diseases - Payers and health systems that determine reimbursement and access - Clinical trial sites and investigators running development studies - Licensing and partnering counterparties in biopharma - Contract manufacturers supplying clinical and future commercial material ## Geography Artelo is headquartered in Solana Beach, California and is based in the United States, but its business model is not tied to a large commercial footprint yet because it has no product revenue. The company disclosed that it is conducting clinical trials in the UK, which also makes it eligible for UK R&D tax credits subject to changing rules. Management also refers to the possibility of commercialization in the United States or overseas, indicating that future market access could be international. Geography matters mainly through clinical trial execution, regulatory approvals, manufacturing supply chains, and tax-credit eligibility rather than through current sales concentration. As the pipeline advances, the company’s exposure to U.S. and foreign regulatory regimes will become more important. - Headquartered in Solana Beach, California, United States - Clinical trials are being conducted in the United Kingdom - Future commercialization could be in the United States or overseas - UK R&D tax credits are part of the current funding profile - Regulatory approvals will be country-specific and market access driven ## Strategy Artelo’s strategy is to build a pipeline around lipid-signaling modulation, including the endocannabinoid system, and to focus on therapeutic areas with validated biology and unmet medical need. The company is prioritizing ART12.11 for anxiety disorders and rare/orphan diseases based on preclinical results and a commercial precedent for CBD-containing products in a rare-disease setting. It also intends to continue licensing intellectual property from pharmaceutical and biotechnology companies and research institutions to expand its pipeline. Because it has no internal sales and marketing organization, the company may partner for commercialization or build those capabilities later if development succeeds. The strategy is therefore centered on scientific differentiation, IP access, and capital-efficient development until a product candidate is approvable. - **Advance ART12.11 development** (short-term) — The program is a key differentiated asset and the company’s disclosed anxiety and rare-disease strategy centers on it. - **Expand the pipeline through licensing** (medium-term) — Artelo relies on in-licensed IP to build a broader portfolio without having to originate every asset internally. - **Secure development and commercialization partners** (medium-term) — The company lacks internal sales, marketing, and distribution capabilities and may need partners to reach market. - **Preserve capital and extend runway** (short-term) — As a clinical-stage company with no revenue, financing discipline is essential to keep programs moving. - Advance lipid-signaling and ECS-based therapeutics with validated biology - Develop ART12.11 for anxiety disorders and rare/orphan diseases - Use licensing to add research-stage and clinical-stage assets - Pursue partnering where it maximizes stockholder value - Maintain flexibility on internal commercialization versus third-party deals - Focus on indications with unmet medical need and commercial potential ## Risks Artelo is exposed to the classic risks of a clinical-stage biotech company: it has no product revenue, limited operating history, and a high dependence on external financing to fund development. Its pipeline depends on successful clinical execution, regulatory approvals, and the ability to maintain rights under third-party licenses, any of which could delay or terminate programs. The company also depends on contract manufacturers and third-party service providers, so supply-chain or quality failures could disrupt trials. More broadly, cannabinoid-derived and ECS-based therapies face scientific, regulatory, reimbursement, and competitive risks because the market includes large pharmaceutical companies, biotech peers, and alternative treatments. UK R&D tax credit rules, changing health-care regulation, and market acceptance of any approved product are additional business-specific uncertainties. - **Additional financing risk** [critical] — The company has no product revenue and must fund research, trials, and operations through external capital. - **Clinical development and regulatory delay** [high] — Trial timing and approval outcomes are uncertain and can be affected by protocol, safety, or regulatory issues. - **License compliance and IP loss** [high] — The business depends on third-party patent licenses that are vital to its development programs. - **Manufacturing and supply-chain dependence** [high] — A third-party CMO supplies materials for clinical trials, creating execution and quality risk. - **Competitive market for cannabinoid-derived therapies** [medium] — The company competes against approved therapies, emerging biotech programs, and academic research. - **UK R&D tax credit policy changes** [medium] — The company currently benefits from UK R&D tax credits tied to clinical trial activity. - Need for additional financing could force dilution or limit operations - Clinical trial delays can push back regulatory milestones and increase costs - Loss of licensed IP rights could impair the core pipeline - Contract manufacturing failures could disrupt trial supply and timelines - Competitive pressure from larger pharma and biotech companies is intense - Regulatory and reimbursement uncertainty may limit future commercialization - UK R&D tax credit rule changes may reduce non-dilutive funding ## Accounting Artelo’s accounting is dominated by development-stage judgments rather than revenue recognition, because it has not generated product revenue to date. Research and development costs are expensed as incurred, so quarterly results can swing materially depending on trial activity, licensing costs, and preclinical work. General and administrative expense includes stock-based compensation, professional fees, and executive/director compensation, which can be significant relative to the company’s small scale. The company also reports other income from interest income and changes in fair value of trading marketable securities, so market movements can affect non-operating results. Investors should also watch the accounting treatment of convertible notes, equity issuances, and UK R&D tax credits, since these can materially affect reported liquidity and net loss. - **Research and development expense recognition** — Quarterly operating loss and comparability - **Stock-based compensation** — General and administrative expense and dilution analysis - **Fair value of trading marketable securities** — Net loss and non-operating income - **UK R&D tax credits** — Cash flow and effective development cost - **Convertible notes and equity financing** — Capital structure and per-share metrics - R&D is expensed as incurred, making results highly dependent on trial timing - Clinical-stage spending can create large quarter-to-quarter swings in operating loss - Stock-based compensation is a meaningful G&A component for a small biotech - Fair value changes in trading securities affect other income and net loss - Convertible notes and equity issuances affect capital structure and dilution - UK R&D tax credits can reduce net expense and improve reported cash flow --- *Last updated: 2026-09-24T11:31:42.935005+00:00*